Advertisement
ABBV vs JNJ
Which Stock Would AI Choose? AbbVie (ABBV) vs. Johnson & Johnson (JNJ) Stock Comparison
Key Takeaways
- AbbVie reported full-year 2025 revenue of $61.16 billion, reflecting 8.6% growth, outpacing Johnson & Johnson's 6.0% increase to $94.2 billion.
- Both companies operate in the healthcare sector with significant exposure to immunology and oncology, though AbbVie maintains a more concentrated biopharmaceutical focus while Johnson & Johnson balances pharmaceuticals with its MedTech division.
- Recent market activity shows AbbVie delivering stronger top-line momentum driven by Skyrizi and Rinvoq, whereas Johnson & Johnson benefited from Q2 2026 results that prompted raised full-year guidance.
- Johnson & Johnson received FDA marketing authorization for its OTTAVA robotic surgical system in recent weeks, adding a catalyst in MedTech, while AbbVie advanced pipeline initiatives including acquisitions in immunology.
- Valuation metrics indicate AbbVie trading at a forward price-to-earnings ratio of approximately 17–18, with Johnson & Johnson reflecting a modestly lower multiple amid litigation considerations.
- One-year stock returns through mid-2026 favored AbbVie with approximately 37% appreciation compared to Johnson & Johnson's performance amid broader sector stability.
Introduction
AbbVie and Johnson & Johnson represent two established players in the healthcare sector, each with distinct business models and growth trajectories that appeal to investors seeking stability alongside innovation exposure. This comparison examines their relative positioning through the lens of recent financial results, operational developments, and market sentiment. The analysis targets portfolio managers, sector-focused traders, and long-term investors evaluating large-cap pharmaceutical and medical technology names for diversification or tactical allocation in a market environment shaped by patent dynamics, regulatory approvals, and earnings momentum.
AbbVie Overview and Recent Performance
AbbVie is a research-based biopharmaceutical company with a primary focus on immunology, oncology, and neuroscience. Following the loss of exclusivity for its former flagship product Humira, the company has transitioned successfully to a portfolio led by Skyrizi and Rinvoq, which together exceeded $25 billion in 2025 sales. In recent market activity, AbbVie has demonstrated resilience through 8.6% full-year 2025 revenue growth to $61.16 billion. Pipeline advancements, including the acquisition of Capstan Therapeutics and licensing deals in obesity and immunology, have supported sentiment. The company issued 2026 adjusted earnings per share guidance of $14.37–$14.57, signaling expected acceleration from a prior acquisition-impacted base. Stock performance has reflected investor confidence in this post-transition growth narrative.
Johnson & Johnson Overview and Recent Performance
Johnson & Johnson operates across Innovative Medicine and MedTech segments, with key strengths in oncology, immunology, and surgical technologies. The company reported second-quarter 2026 sales of $25.3 billion, marking 6.6% reported growth and prompting an upward revision to full-year guidance of approximately $101.1 billion in revenue and $11.68 in adjusted earnings per share. Recent developments include U.S. FDA marketing authorization for the OTTAVA robotic surgical system, enhancing MedTech positioning. Despite headwinds from Stelara loss of exclusivity, the firm maintains a diversified revenue base that includes a substantial MedTech contribution. Year-to-date stock gains have approximated 27–28%, supported by multiple analyst price target increases following the earnings release.
Trending AI Robots
Tickeron maintains a curated section known as Trending AI Robots, which highlights select AI trading bots from a broader library of hundreds available across thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions, including consistent trend capture, risk-adjusted returns, and adaptability across varying timeframes, earn placement in this featured area. Available bots span diverse strategies, performance ranges, and ticker universes, with statistics often showing win rates between 55% and 75% alongside varying drawdown profiles depending on the specific model. This resource provides traders with data-driven options for automated execution without favoring any single approach. Explore the full selection at the Trending AI Robots page for further details.
Head-to-Head Comparison
AbbVie operates as a more concentrated biopharmaceutical entity, with roughly half of recent revenue derived from immunology assets that have delivered outsized growth following the Humira transition. This focus creates higher sensitivity to pipeline execution but has translated into superior top-line expansion relative to peers. Johnson & Johnson employs a two-pillar structure that incorporates a sizable MedTech segment, offering earnings stability and insulation from individual product patent expirations, though it introduces exposure to device regulatory and litigation factors such as ongoing talc matters. Momentum contrasts appear in recent performance, with AbbVie posting stronger 2025 revenue growth and higher expected 2026 earnings acceleration. Sector exposure overlaps in oncology and immunology, yet Johnson & Johnson's broader diversification and recent robotic surgery authorization provide distinct catalysts. Valuation and risk trade-offs reflect these profiles, with AbbVie commanding a premium multiple for growth visibility while Johnson & Johnson trades at a discount that partially accounts for litigation overhangs.
Tickeron AI Verdict
Based on observable factors including trend consistency, earnings momentum, and relative growth positioning, Tickeron’s AI models currently assign a modestly higher probabilistic preference to AbbVie. The company’s demonstrated post-transition revenue acceleration and forward earnings guidance provide clearer near-term visibility compared with Johnson & Johnson’s balanced but slower-growth profile amid ongoing portfolio adjustments. This assessment remains probabilistic and subject to shifts in market conditions or new developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a StrongBuy and JNJ is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 3 FA rating(s) are green whileJNJ’s FA Score has 4 green FA rating(s).
- ABBV’s FA Score: 3 green, 2 red.
- JNJ’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 4 TA indicator(s) are bullish while JNJ’s TA Score has 3 bullish TA indicator(s).
- ABBV’s TA Score: 4 bullish, 3 bearish.
- JNJ’s TA Score: 3 bullish, 4 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +2.58% price change this week, while JNJ (@Pharmaceuticals: Major) price change was +1.91% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.89%. For the same industry, the average monthly price growth was -0.90%, and the average quarterly price growth was +1.95%.
Reported Earning Dates
ABBV is expected to report earnings on Oct 23, 2026.
JNJ is expected to report earnings on Oct 20, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.89% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ABBV | JNJ | ABBV / JNJ | |
| Capitalization | 442B | 626B | 71% |
| EBITDA | 16.9B | 34B | 50% |
| Gain YTD | 12.041 | 26.931 | 45% |
| P/E Ratio | 70.65 | 30.14 | 234% |
| Revenue | 62.8B | 97.9B | 64% |
| Total Cash | N/A | 20.8B | - |
| Total Debt | 72.9B | 49B | 149% |
ABBV | JNJ | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 76 | 35 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 44 Fair valued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 7 | 6 | |
SMR RATING 1..100 | 1 | 38 | |
PRICE GROWTH RATING 1..100 | 28 | 23 | |
P/E GROWTH RATING 1..100 | 80 | 14 | |
SEASONALITY SCORE 1..100 | 44 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (12) in the Pharmaceuticals Major industry is in the same range as ABBV (44). This means that JNJ’s stock grew similarly to ABBV’s over the last 12 months.
JNJ's Profit vs Risk Rating (6) in the Pharmaceuticals Major industry is in the same range as ABBV (7). This means that JNJ’s stock grew similarly to ABBV’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is somewhat better than the same rating for JNJ (38). This means that ABBV’s stock grew somewhat faster than JNJ’s over the last 12 months.
JNJ's Price Growth Rating (23) in the Pharmaceuticals Major industry is in the same range as ABBV (28). This means that JNJ’s stock grew similarly to ABBV’s over the last 12 months.
JNJ's P/E Growth Rating (14) in the Pharmaceuticals Major industry is significantly better than the same rating for ABBV (80). This means that JNJ’s stock grew significantly faster than ABBV’s over the last 12 months.
| ABBV | JNJ | |
|---|---|---|
| RSI ODDS (%) | N/A | 6 days ago 34% |
| Stochastic ODDS (%) | 2 days ago 70% | 2 days ago 51% |
| Momentum ODDS (%) | 2 days ago 37% | 2 days ago 50% |
| MACD ODDS (%) | 2 days ago 44% | 2 days ago 35% |
| TrendWeek ODDS (%) | 2 days ago 62% | 2 days ago 46% |
| TrendMonth ODDS (%) | 2 days ago 65% | 2 days ago 49% |
| Advances ODDS (%) | 2 days ago 60% | 8 days ago 45% |
| Declines ODDS (%) | 9 days ago 48% | 14 days ago 42% |
| BollingerBands ODDS (%) | 2 days ago 64% | N/A |
| Aroon ODDS (%) | 2 days ago 62% | 2 days ago 45% |
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with NVS. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then NVS could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +0.85% | ||
| NVS - ABBV | 52% Loosely correlated | -1.39% | ||
| BMY - ABBV | 50% Loosely correlated | -1.90% | ||
| JNJ - ABBV | 47% Loosely correlated | -0.77% | ||
| MRK - ABBV | 46% Loosely correlated | -0.38% | ||
| AMGN - ABBV | 46% Loosely correlated | -0.70% | ||
More | ||||
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.